The relation of adipose tissue to cardiometabolic risk (Q36701768)

15 August 2017

1 reference

title

The relation of adipose tissue to cardiometabolic risk (English)

1 reference

15 August 2017

F Xavier Pi-Sunyer

1

1 reference

15 August 2017

1 January 2006

1 reference

15 August 2017

1 reference

15 August 2017

8 Suppl 4

1 reference

15 August 2017

S14-23

1 reference

Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association

15 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Insulin resistance and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

A prospective study of obesity and risk of coronary heart disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Overweight and obesity as determinants of cardiovascular risk: the Framingham experience.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Glucose, insulin concentrations and obesity in childhood and adolescence as predictors of NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Weight gain as a risk factor for clinical diabetes mellitus in women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Adipose tissue, adipokines, and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Adipose tissue as an endocrine organ

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Adipose tissue as a secretory organ: from adipogenesis to the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Adipose tissue as an endocrine and paracrine organ

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Signalling role of adipose tissue: adipokines and inflammation in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Minireview: Adiposity, Inflammation, and Atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

The metabolic syndrome and adipocytokines

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Adipokines: inflammation and the pleiotropic role of white adipose tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

The delicate balance between fat and muscle: adipokines in metabolic disease and musculoskeletal inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Obesity and the role of adipose tissue in inflammation and metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Adiponectin and Metabolic Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Cardioprotection by adiponectin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Leptin, from fat to inflammation: old questions and new insights.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Leptin: a metabolic hormone that functions like a proinflammatory adipokine.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Adipose tissue and atherothrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

The epidemiology of central fat distribution in relation to disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980040-2

7 January 2021

10.1016/S1098-3597(06)80040-2

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17208662